| Luis Alberto Vega, RN | |
|
392 Ave Jose De Diego W, Cayey, PR 00736-3747 | |
| (787) 763-7575 | |
| (787) 263-4224 |
| Full Name | Luis Alberto Vega |
|---|---|
| Gender | Male |
| Speciality | Registered Nurse - Psychiatric/mental Health, Adult |
| Location | 392 Ave Jose De Diego W, Cayey, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285948562 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WP0809X | Registered Nurse - Psychiatric/mental Health, Adult | 00317 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Luis Alberto Vega, RN Po Box 607087, Bayamon, PR 00960-7087 Ph: (787) 763-7575 | Luis Alberto Vega, RN 392 Ave Jose De Diego W, Cayey, PR 00736-3747 Ph: (787) 763-7575 |
News Archive
Scientists at The Scripps Research Institute have shown that an injectable solution can protect mice from an otherwise lethal overdose of cocaine. The findings could lead to human clinical trials of a treatment designed to reverse the effects of cocaine in case of emergency. Cocaine is involved in more than 400,000 emergency-room visits and about 5,000 overdose deaths each year in the United States.
The concept sounds ideal: vaccines made of DNA that could be taken in by other cells and give instructions for how to fight off different diseases. The reality, however, has fallen short. Although DNA vaccines have been around for about 15 years and shown lots of promise for HIV, SARS and influenza vaccines during preclinical testing in mice, researchers have yet to make them potent enough to be helpful in humans.
Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.
Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.
› Verified 7 days ago
Mrs. Mayra Colon Rivera, RN, BSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: I19 Calle Margarita, Urb. Jardines De Cayey Ii, Cayey, PR 00736 Phone: 787-557-9105 | |
Alicia Gomez, L.P.N. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 392 Ave Jose De Diego W, Cayey, PR 00736 Phone: 787-763-7575 Fax: 787-263-4224 | |
Martin Santiago, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: D32 Calle Jade, Urb La Plata, Cayey, PR 00736 Phone: 787-307-5615 | |
Nancy Colon, R.N. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 392 Ave Jose De Diego W, Cayey, PR 00736 Phone: 787-738-3705 Fax: 787-263-4224 | |
Carmen Martinez, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 392 Ave Jose De Diego W, Cayey, PR 00736 Phone: 787-677-5043 Fax: 787-263-4224 | |
Mr. Emmanuel Alberto Ortiz Colon, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: Carretera Estatal Pr #14, Interior, Km 0.3,, Barrio Rincon, Sector Lomas, Cayey, PR 00736 Phone: 787-535-1001 |